NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ICCM

Icecure Medical Ltd

Jun 30 • 04:00PM ET

0.9955

Dollar change -0.0145
Percentage change -1.44	%

Healthcare • Medical Devices • Israel • NASD

Peers: BMRN NBIX ANIK BLFS CRIS OSUR QURE TGTX VRTX XBIT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	49.23%	Shs Outstand	58.62M	Perf Week	8.19%
Market Cap	56.31M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	0.00%	Shs Float	28.72M	Perf Month	-3.35%
Enterprise Value	50.65M	PEG	-	EPS next Q	-0.06	Inst Own	0.23%	Short Float	0.72%	Perf Quarter	-10.32%
Income	-15.30M	P/S	17.22	EPS this Y	28.89%	Inst Trans	-16.52%	Short Ratio	0.86	Perf Half Y	-10.32%
Sales	3.27M	P/B	9.73	EPS next Y	21.87%	ROA	-112.66%	Short Interest	0.21M	Perf YTD	-9.50%
Book/sh	0.10	P/C	9.32	EPS next 5Y	-	ROE	-173.47%	52W High	1.66 -40.03%	Perf Year	33.75%
Cash/sh	0.11	P/FCF	-	EPS past 3/5Y	4.58% 2.44%	ROIC	-250.44%	52W Low	0.48 107.40%	Perf 3Y	-44.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-7.35% 15.36%	Gross Margin	42.77%	Volatility	10.66% 6.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	15.49	EPS Y/Y TTM	9.38%	Oper. Margin	-479.77%	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.48	Sales Y/Y TTM	0.34%	Profit Margin	-467.37%	RSI (14)	47.39	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	19.43%	SMA20	-0.07%	Beta	-	Target Price	3.01
Payout	-	Debt/Eq	0.06	Sales Q/Q	-2.42%	SMA50	-5.29%	Rel Volume	1.15	Prev Close	1.01
Employees	72	LT Debt/Eq	0.02	Earnings	May 28 BMO	SMA200	-1.59%	Avg Volume	240.54K	Price	1.00
IPO	Nov 07, 2013	Option/Short	No / Yes	EPS/Sales Surpr.	25.00% -3.33%	Trades		Volume	276,809	Change	-1.44%

Jun-25-25 09:23AM	IceCure Announces Record Date for Rights Offering for Up to $10 Million (PR Newswire)
Jun-09-25 08:30AM	IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes (PR Newswire)
May-29-25 07:00PM	Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ... (GuruFocus.com)
May-28-25 08:30AM	IceCure Medical Reports First Quarter 2025 Financial Results (PR Newswire) -8.85%
May-27-25 09:22AM	Icecure Medical Ltd (ICCM) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +6.60%
08:30AM	Loading…
May-21-25 08:30AM	IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025 (PR Newswire)
May-12-25 05:05PM	Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.83% +6.87%
May-08-25 05:55PM	Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 08:30AM	IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense Cryoablation (PR Newswire)
Apr-30-25 08:30AM	IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense Cryoablation in Women 70+ with Early-Stage Breast Cancer (PR Newswire)
Apr-28-25 08:30AM	IceCure Exhibits ProSense & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium (PR Newswire)
Apr-22-25 08:30AM	IceCure's ProSense Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation (PR Newswire)
Mar-28-25 09:16AM	IceCure Medical Stock Dips Despite Positive ICESECRET Study Results (Zacks)
Mar-27-25 01:45PM	IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:30AM	IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense Cryoablation Sales in North America (PR Newswire)
08:30AM	Loading…
Mar-24-25 08:30AM	IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate (PR Newswire)
Mar-21-25 08:30AM	IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 (PR Newswire)
Mar-20-25 11:02AM	IceCure tumbles after updating plans to seek FDA nod for ProSense (SeekingAlpha) -15.54%
08:30AM	IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense Cryoablation in Early-Stage Breast Cancer (PR Newswire)
Mar-18-25 08:30AM	IceCure's ProSense Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference (PR Newswire)
Mar-17-25 08:30AM	IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology (PR Newswire) +7.04%
Mar-10-25 08:30AM	Breast Cancer Patients who Underwent IceCure's ProSense Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery (PR Newswire)
Feb-25-25 07:15AM	IceCure seeks Israeli regulatory approval for XSense cryoablation system (Medical Device Network)
Feb-24-25 08:30AM	IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense Cryoablation System in Israel (PR Newswire)
Feb-04-25 08:30AM	IceCure's ProSense in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision (PR Newswire)
Jan-28-25 07:43AM	IceCure submits application to Chinas NMPA for cryoablation system approval (Medical Device Network)
Jan-27-25 08:30AM	IceCure Files for Regulatory Approval of ProSense Cryoablation System in China (PR Newswire)
Jan-13-25 07:00AM	IceCure Medical CEO Issues Letter to Shareholders and Reports Increase of 42% in ProSense Sales for 2024 in North America (PR Newswire) -9.96%
07:00AM	IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America (PR Newswire)
Jan-06-25 08:30AM	IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule (PR Newswire) +5.38%
08:30AM	Loading…
Jan-03-25 08:30AM	European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology (PR Newswire) +5.69%
Dec-16-24 08:30AM	Data on IceCure's ProSense Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting (PR Newswire)
Dec-05-24 08:30AM	IceCure's ProSense Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results (PR Newswire)
Nov-26-24 09:40AM	IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:30AM	IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense Cryoablation (PR Newswire)
Nov-25-24 08:30AM	IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office (PR Newswire) +9.13%
Nov-20-24 08:30AM	IceCure Medical to Report Third Quarter 2024 Financial and Operational Results on November 26, 2024 (PR Newswire)
08:30AM	IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 (PR Newswire)
Nov-19-24 08:30AM	IceCure's ProSense Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health (PR Newswire)
Nov-11-24 06:35AM	IceCures cryoablation system for breast cancer treatment gains FDA panel support (Medical Device Network) -6.77%
Nov-08-24 07:00AM	FDA Advisory Panel Votes in Favor of IceCure's ProSense Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer (PR Newswire) -11.73%
Oct-29-24 08:30AM	Upcoming FDA Advisory Panel for IceCure's ProSense Marketing Authorization Receives Large Number of Public Comments from Stakeholders (PR Newswire) +18.18%
Oct-21-24 08:30AM	IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System (PR Newswire) +7.50%
Oct-07-24 08:15AM	IceCure's ProSense Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference (PR Newswire)
Sep-24-24 08:15AM	IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate (PR Newswire)
Sep-16-24 08:00AM	Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues (PR Newswire)
Sep-12-24 08:00AM	IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 (PR Newswire)
Sep-04-24 08:30AM	IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences (PR Newswire)
Aug-28-24 08:30AM	USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies (PR Newswire) -5.42%
Aug-20-24 12:52PM	ICCM Stock Earnings: Icecure Medical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +18.18%
09:40AM	IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	IceCure Medical Reports 20% Growth in ProSense System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets (PR Newswire)
Aug-14-24 08:30AM	IceCure's ProSense Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery (PR Newswire)
Aug-13-24 08:30AM	IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 (PR Newswire)
Aug-07-24 08:30AM	IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: 'Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials' (PR Newswire)
Jul-22-24 11:53AM	IceCure presents hat-trick of positive trial data for cryoablation device (Medical Device Network) -6.66%
08:30AM	99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society (PR Newswire)
04:52AM	IceCure Medical receives Nasdaq compliance notice (Medical Device Network)
Jul-19-24 04:30PM	IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Jul-11-24 01:22PM	IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint (Zacks)
Jul-09-24 08:30AM	European Study Provides More Evidence Supporting IceCure's ProSense is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer (PR Newswire)
Jul-03-24 11:50AM	IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod (Zacks)
Jul-02-24 05:52AM	FDA grants marketing authorisation for IceCures XSense Cryoablation System (Medical Device Network)
Jul-01-24 08:30AM	U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes (PR Newswire)
Jun-18-24 08:30AM	IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 (PR Newswire)
Jun-17-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -6.00%
Jun-12-24 08:30AM	Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function (PR Newswire)
Jun-04-24 12:00PM	IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade (Zacks) -7.62%
08:30AM	FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense, Decision Expected Early 2025; Aligns with Commercial Readiness Plan (PR Newswire)
May-28-24 12:52PM	ICCM Stock Earnings: Icecure Medical Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:30AM	IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 (PR Newswire)
May-21-24 08:30AM	IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024 (PR Newswire)
May-20-24 08:30AM	IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase (PR Newswire)
May-07-24 08:30AM	Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense, Adding to Continued Positive Data Published Globally (PR Newswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-18-24 11:07AM	IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA (Zacks)
Apr-15-24 08:35AM	IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer (PR Newswire) +8.00%
Apr-04-24 09:28AM	IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-03-24 12:52PM	ICCM Stock Earnings: Icecure Medical Meets EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.72%
08:30AM	IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance (PR Newswire)
Apr-02-24 08:30AM	IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes (PR Newswire)
Mar-27-24 08:30AM	IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 (PR Newswire)
Mar-19-24 08:30AM	IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy (PR Newswire)
Mar-12-24 08:30AM	IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes (PR Newswire)
Mar-07-24 08:30AM	IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference (PR Newswire)
Mar-04-24 08:30AM	IceCure's ProSense a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 (PR Newswire)
Feb-27-24 08:00AM	Fourth BRIIT Conference in India Features IceCure's ProSense in Breast Cancer Imaging & Interventions Workshop (PR Newswire)
Feb-26-24 08:00AM	Study Using IceCure's ProSense Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer (PR Newswire)
Feb-15-24 08:00AM	IceCure's ProSense to be Featured at Two Upcoming Medical Conferences in Japan (PR Newswire)
Jan-30-24 08:00AM	U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense for Early-Stage Breast Cancer (PR Newswire) +7.25%
Jan-29-24 08:00AM	IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class (PR Newswire)
Jan-16-24 08:00AM	IceCure Medical's ProSense Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation (PR Newswire)
Jan-12-24 04:05PM	IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule (GlobeNewswire) -7.04%
Jan-10-24 08:00AM	IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results (PR Newswire) +6.82%
Jan-03-24 08:00AM	New Study Reports IceCure's ProSense Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response (PR Newswire) +7.76%
Dec-13-23 08:00AM	Study Using IceCure's ProSense Finds: 'Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients' (PR Newswire)
Nov-29-23 08:00AM	IceCure's ProSense Deepens Regulatory Approval in India (PR Newswire) -17.34%
Nov-28-23 01:41PM	5 Investors Betting Big on IceCure Medical (ICCM) Stock (InvestorPlace) +83.11%
08:00AM	IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate (PR Newswire)
Nov-15-23 09:15AM	IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ICCM

Icecure Medical Ltd

Upgrade your FINVIZ experience